Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03629418

Targeted Blood-pressure Management and Acute Kidney Injury After Coronary Artery Bypass Surgery

Acute renal injury (AKI) is a common complication after cardiac surgery and is associated with worse outcomes. It is now realized that intraoperative hypotension is an important risk factor for the development of AKI. In a recent randomized controlled trial of patients undergoing major noncardiac surgery, intraoperative individualized blood-pressure management reduced the incidence of postoperative organ dysfunction. The investigators hypothesize that, for patients undergoing off-pump CABG, targeted blood-pressure management during surgery may also reduce the incidence of postoperative AKI.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Acute renal injury (AKI) is a common complication after cardiac surgery. In patients undergoing noncardiac surgery, intraoperative hypotension may lead to hypoperfusion of important organs and result in organ injuries such as AKI, myocardial injury, and stroke. The development of organ injuries is associated with wose outcomes including higher 30-day or even 1-year mortality. In a recent randomized controlled trial, patients undergoing major noncardiac surgery received either individualized (systolic blood pressure [SBP] maintained within 10% of the reference level) or standard (SBP maintained above 80 mmHg or within 40% of the reference level) blood-pressure management strategy during surgery. The results showed that individualized blood-pressure management reduced the incidence of postoperative organ dysfunction. Intraoperative hypotension is very common during off-pump coronary artery bypass grafting (CABG) surgery. The investigators hypothesize that, for patients undergoing off-pump CABG, good blood-pressure management with norepinephrine may also reduce the incidence of postoperative AKI. The purpose of this study is to investigate the effect of targeted blood-pressure management during off-pump CABG surgery on the incidence of postoperative AKI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 50 years;
  • Scheduled to undergo off-pump CABG surgery.

Exclusion criteria

  • Refuse to participate;
  • Untreated or uncontrolled severe hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg);
  • Chronic kidney disease with a glomerular filtration rate < 30 ml/min/1.73 m2 or end-stage renal disease requiring renal-replacement therapy;
  • Inability to communicate during the preoperative period because of coma, profound dementia, language barrier, or end-stage disease;
  • Requirement of vasopressors/inotropics to maintain blood pressure before surgery;
  • Second or emergency surgery;
  • Expected survival of less than 24 hours.

Treatment and study plan

Targeted blood-pressure management

Drug

Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.

Other names: Norepinephrine

Routine blood-pressure management

Drug

Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.

Other names: Phenylephrine and other vasopressors

Primary outcomes

  1. Incidence of acute kidney injury (AKI) within 7 days after surgery

    Time frame: Up to 7 days after surgery

    Development of AKI within 7 days after surgery is diagnosed according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria

Secondary outcomes

  1. Classification of AKI within 7 days after surgery

    Time frame: Up to 7 days after surgery

    Development of AKI within 7 days after surgery is diagnosed according to the KDIGO criteria

  2. Incidence of delirium within 7 days after surgery

    Time frame: Up to 7 days after surgery

    Development of delirium within 7 days after surgery is assessed with the Confusion Assessment Method (3D-CAM for patients without mechanical ventilation and CAM-ICU for patients with mechanical ventilation).

  3. Duration of mechanical ventilation after surgery

    Time frame: Up to 30 days after surgery

    Duration of mechanical ventilation after surgery

  4. Length of stay in intensive care unit (ICU) after surgery

    Time frame: Up to 30 days after surgery

    Length of stay in intensive care unit (ICU) after surgery

  5. Length of stay in hospital after surgery

    Time frame: Up to 30 days after surgery

    Length of stay in hospital after surgery

  6. Incidence of major adverse cardiovascular events (MACEs) within 30 days after surgery

    Time frame: Up to 30 days after surgery

    MACEs within 30 days after surgery include cardiovascular death, non-fatal cardiac arrest, acute myocardial infarction, revascularization, and stroke.

  7. Incidence of non-MACE complications within 30 days after surgery

    Time frame: Up to 30 days after surgery

    Non-MACE complications within 30 days after surgery indicate new-onset medical conditions other than MACEs that produce harmful effects on patients' recovery and required therapeutic intervention.

  8. All-cause 30-day mortality

    Time frame: At 30 days after surgery

    All-cause 30-day mortality

  9. 2-year overall survival after surgery

    Time frame: Up to 2 years after surgery

    2-year overall survival after surgery

  10. 2-year major adverse cardiovascular event (MACE)-free survival after surgery

    Time frame: Up to 2 years after surgery

    MACEs within 2 years after surgery include cardiovascular death, non-fatal cardiac arrest, acute myocardial infarction, revascularization, and stroke.

  11. Cognitive function in 1- and 2-year survivors

    Time frame: At the end of the 1st and 2nd years after surgery

    Cognitive function in 1- and 2-year survivors is assessed with the modified Telephone Interview for Cognitive Status (TICS-m, score ranges from 0 to 40, with higher score indicating better function).

  12. Quality of life in 1- and 2- year survivors: SF-36

    Time frame: At the end of the 1st and 2nd years after surgery

    Quality of life in 1- and 2-year survivors is assessed with the 36-Item Short Form Health Survey (SF-36). The SF-36 evaluates 8 different domains of quality of life, i.e., physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The score of each domain ranges from 0 to 100, with high score indicating better function.

Other outcomes

  1. Pain severity within 3 days after surgery: NRS

    Time frame: Up to 3 days after surgery

    Pain severity is assessed with the Numeric Rating Scale (NRS, an 11-point scale where 0=no pain and 10=the worst pain) twice daily (8:00-10:00 am, 18:00-20:00 pm) after surgery.

  2. Daily prevalence of delirium during postoperative days 1-7

    Time frame: During the first 7 days after surgery

    Daily prevalence of delirium during postoperative days 1-7

  3. Duration of intraoperative cerebral desaturation (sub-study)

    Time frame: During surgery

    Duration of cerebral desaturation is monitored by near-infrared spectroscopy. Cerebral desaturation is defined as a decrease of more than 10% from baseline. Performed in part of enrolled patients.

Study contacts

Contact information is provided by the study sponsor or research team.

Dong-Xin Wang, MD, PhD

CONTACT

[email protected]

8610-83572784

Li Huang, MD, PhD

CONTACT

[email protected]

8610-83572460

Sponsors and collaborators

Lead sponsor

Peking University First Hospital

Other

Registry information

Official study title

Impact of Targeted Blood-pressure Management on Incidence of Acute Kidney Injury After Off-pump Coronary Artery Bypass Surgery: A Randomized Controlled Trial

Important dates

Study start
2018
Primary completion
2025
Study completion
2026
First posted
Aug 14, 2018
Registry last updated
Jul 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.